AR016387A1 - Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos - Google Patents

Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos

Info

Publication number
AR016387A1
AR016387A1 ARP980103776A ARP980103776A AR016387A1 AR 016387 A1 AR016387 A1 AR 016387A1 AR P980103776 A ARP980103776 A AR P980103776A AR P980103776 A ARP980103776 A AR P980103776A AR 016387 A1 AR016387 A1 AR 016387A1
Authority
AR
Argentina
Prior art keywords
substituted
heterocyclic
compounds
group
aryl
Prior art date
Application number
ARP980103776A
Other languages
English (en)
Original Assignee
Athena Neurosciences Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc, American Home Prod filed Critical Athena Neurosciences Inc
Publication of AR016387A1 publication Critical patent/AR016387A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos que se adhieren a VLA-4. Algunos de estos compuestos inhiben también la adhesion de leucocitos y en particular, la adhesion deleucocitos intermediada por VLA-4. Dichos compuestos son utiles para el tratamiento de enfermedadesinflamatorias en un paciente mamífero, por ejemplo en unser humano, tal como asma, enfermedad de Alzheimer, ateroesclerosis, demencia causada por SIDA, diabetes, enfermedad inflamatoria del intestino, artritisreumatoide, transplantes de tejidos, metástasis de tumores e isquemia de miocardio. Los componentes pueden administrarse también para el tratamiento deenfermedades inflamatorias del cerebro tales como esclerosis multiple. Los compuestos de la formula I donde R1 está seleccionado del grupo que consiste enalquilo, alquilo sustituido, arilo, arilo sustituido, cicloalquilo, cicloalquilo sustituido, heterocíclico, heterocíclico sustituido, heteroarilo yheteroarilo sustituido. R2 está seleccionado del grupo que consiste en hidrogeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido,cicloalquenilo, cicloalquenilo sustituido, heterocíclico, heterocíclico sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, y R1 y R2conjuntamente con el átomo de nitrogeno unido a R2 y el grupo SO2 unido a R1 pueden formar un grupo heterocíclico o heterocíclico sustituido; R3 estárelacionado del grupo que consiste en alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilosustituido, heterocíclico, heterocíclico sustituido y cuando R2 no forma un grupo heterocíclico con R1 y R2 y R3 conjuntamente con el átomo de nitrogenoadherido a R2 y el átomo de carbono adherido a R3, pueden formar un grupo heterocíclico o heterocíclico sustituido; R4 está seleccionado del grupo que consisteen alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, y, cuando R3 no forma un grupo heteroc'cilico con R2, entonces R3y R4 conjuntamente con átomo de carbono al cual están unidos pueden formar un cicloalquilo, cicloalquilo sustituido, un heterocíclico o un grupo heterocíclico
ARP980103776A 1997-07-31 1998-07-30 Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos AR016387A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90441597A 1997-07-31 1997-07-31

Publications (1)

Publication Number Publication Date
AR016387A1 true AR016387A1 (es) 2001-07-04

Family

ID=25419114

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103776A AR016387A1 (es) 1997-07-31 1998-07-30 Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos

Country Status (14)

Country Link
EP (1) EP0994895A1 (es)
JP (1) JP2001512137A (es)
KR (1) KR20010022412A (es)
CN (1) CN1265673A (es)
AR (1) AR016387A1 (es)
AU (1) AU8661298A (es)
BR (1) BR9811599A (es)
CA (1) CA2291475A1 (es)
HU (1) HUP0002682A3 (es)
IL (1) IL133642A0 (es)
NO (1) NO20000412L (es)
PL (1) PL338554A1 (es)
WO (1) WO1999006435A1 (es)
ZA (1) ZA986834B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
CA2291708A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
DE69820614T2 (de) * 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough Entzündungshemmende tyrosin-derivate
PT991619E (pt) 1997-06-23 2004-02-27 Upjohn Co Inibidores da adesao celular mediada pela alfa4beta1
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
DE69919334T2 (de) 1998-02-26 2005-08-04 Celltech Therapeutics Ltd., Slough Phenylalaninderivate als inhibitoren von alpha4 integrinen
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
PT1154993E (pt) * 1999-02-18 2005-01-31 Hoffmann La Roche Derivados de tioamida
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CN1377268A (zh) * 1999-08-13 2002-10-30 比奥根公司 细胞粘合抑制剂
IL148544A0 (en) * 1999-09-24 2002-09-12 Genentech Inc Tyrosine derivatives
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP2003519697A (ja) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬
JP2003531141A (ja) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド エナミン誘導体
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6740654B2 (en) 2000-07-07 2004-05-25 Celltech R & D Limited Squaric acid derivatives
WO2002008206A1 (en) * 2000-07-21 2002-01-31 Elan Pharmaceuticals, Inc. 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2004526733A (ja) 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド 強力な細胞接着阻害剤としての置換ｎ−アリールスルホニル−プロリン誘導体
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
CA2561164A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2774919A1 (en) * 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3018126A4 (en) * 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC COMPOUND
EP3018123B1 (en) 2013-07-03 2023-05-10 Takeda Pharmaceutical Company Limited Amide compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
ZA986834B (en) 2000-05-02
HUP0002682A1 (hu) 2001-07-30
CA2291475A1 (en) 1999-02-11
CN1265673A (zh) 2000-09-06
NO20000412L (no) 2000-03-24
BR9811599A (pt) 2000-09-19
NO20000412D0 (no) 2000-01-27
WO1999006435A1 (en) 1999-02-11
HUP0002682A3 (en) 2001-12-28
AU8661298A (en) 1999-02-22
PL338554A1 (en) 2000-11-06
EP0994895A1 (en) 2000-04-26
IL133642A0 (en) 2001-04-30
KR20010022412A (ko) 2001-03-15
JP2001512137A (ja) 2001-08-21

Similar Documents

Publication Publication Date Title
AR016387A1 (es) Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos
AR014903A1 (es) Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria
AR016133A1 (es) Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
BR0007663A (pt) Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
AR013384A1 (es) Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4
BR9811594A (pt) Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
HK1072608A1 (en) Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
BR9811569A (pt) Compostos que inibem a adesão de leucócito mediada por vla-4
DE69841850D1 (de) Differenzierung in osteoblasten der fettgewebe-stromalen zellen und ihre verwendungen
BR9811573A (pt) Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4
ATE464298T1 (de) Heteroaryl-verbindungen zur hemmung der durch alpha-4-integrine vermittelten leukozytenadhäsion
AU2014232275A1 (en) Compounds and matrices for use in bone growth and repair
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2005111020A3 (en) Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
EP2617415B1 (en) Use of a compound for inducing differentiation of mesenchymal stem cells into cartilage cells
AR022405A1 (es) Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos
AR029611A1 (es) Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4
HUT49122A (en) Process for producing pharmaceutical compositions containing pyridyl-ethanol-amine as active component and the active component
DE60112241D1 (de) Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen
EP3165523A2 (en) Composition for inducing cell reprogramming
DE60025036D1 (de) Verfahren zur züchtung von haftenden tierischen zellen
AR026105A1 (es) Compuetos heteroarilo, heterociclico y ilo que
CN105120851A (zh) 用于医疗用途，具体为用于治疗与氧化应激相关的疾病或者炎症和用于保存或者洗涤器官的barettin及其衍生物
Childress et al. The Hematopoietic Stem Cell Niche: Cell-Cell Interactions and Quiescence

Legal Events

Date Code Title Description
FB Suspension of granting procedure